SCOPUS 정보 검색 플랫폼

Journal of Clinical Pharmacology

Volumn 37, Issue 9, 1997, Pages 816-819

Renal dysfunction does not alter the pharmacokinetics or LDL- cholesterol reduction of atorvastatin

(6) Stern, R H a Yang, B B a Horton, M b Moore, S b Abel, R B a Olson, S C a

a PFIZER INC (United States)

b Center for Clinical Research (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION;

EID: 0030870919 PISSN: 00912700 EISSN: None Source Type: Journal
DOI: 10.1002/j.1552-4604.1997.tb05629.x Document Type: Article

Times cited : (63)

References (8)

1
- 12644301168
- Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects
- Cilla DD, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL: Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996;60:687-695.
- (1996) Clin Pharmacol Ther , vol.60 , pp. 687-695
- Cilla, D.D.¹ Whitfield, L.R.² Gibson, D.M.³ Sedman, A.J.⁴ Posvar, E.L.⁵

2
- 0029043903
- Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
- Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromh Vasc Biol 1995;15:678-682.
- (1995) Arterioscler Thromh Vasc Biol , vol.15 , pp. 678-682
- Nawrocki, J.W.¹ Weiss, S.R.² Davidson, M.H.³ Sprecher, D.L.⁴ Schwartz, S.L.⁵ Lupien, P.J.⁶

3
- 0028222224
- Drug dosing in renal insufficiency
- Talbert RL: Drug dosing in renal insufficiency. J Clin Pharmacol 1994;34:99-110.
- (1994) J Clin Pharmacol , vol.34 , pp. 99-110
- Talbert, R.L.¹

4
- 0000705075
- Development and validation of an enzyme inhibition assay for quantitation of CI-981 in human plasma
- Shum YY, Huang H: Development and validation of an enzyme inhibition assay for quantitation of CI-981 in human plasma [abstract]. Pharm Res 1993;10:S-415.
- (1993) Pharm Res , vol.10
- Shum, Y.Y.¹ Huang, H.²

5
- 0030005053
- Effect of age and gender on atorvastatin pharmacokinetics in humans
- Gibson DM, Whitfield LR, Bron NJ, Richens A, Hounslow NJ, Sedman AJ: Effect of age and gender on atorvastatin pharmacokinetics in humans. J Clin Pharmacol 1996;36:242-246.
- (1996) J Clin Pharmacol , vol.36 , pp. 242-246
- Gibson, D.M.¹ Whitfield, L.R.² Bron, N.J.³ Richens, A.⁴ Hounslow, N.J.⁵ Sedman, A.J.⁶

6
- 0026080146
- 14C-lovastatin in chronic renal failure
- 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 1991;50:437-441.
- (1991) Clin Pharmacol Ther , vol.50 , pp. 437-441
- Querin, R.¹ Lambert, R.² Cusson, J.R.³ Gregoire, S.⁴ Vickers, S.⁵ Stubbs, R.J.⁶

7
- 0026813730
- Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment
- Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H: Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992;32:124-132.
- (1992) J Clin Pharmacol , vol.32 , pp. 124-132
- Halstenson, C.E.¹ Triscari, J.² Devault, A.³ Shapiro, B.⁴ Keane, W.⁵ Pan, H.⁶

8
- 0038968339
- Montvale, NJ: Medical Economics Co.
- Physicians Desk Reference, 50th ed. Montvale, NJ: Medical Economics Co. 1996.
- (1996) Physicians Desk Reference, 50th Ed.

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.